QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Phathom Pharmaceuticals, Inc. (PHAT)

Healthcare

No action
Fundamental
3
Sentiment
3
Technical
3

Do Nothing: no qualifying entry — the buy-stop breakout above the settled 6.38 swing high (6.39 trigger, structure stop 5.29) returns R/R 0.96, under the 1.0 floor, and any pullback/oversold limit is trend-gated (price 6.06 below SMA50 6.97 with MACD -0.35 < 0, and below a declining SMA200 with SMA50 < SMA200 and no momentum reclaim — a countertrend bid, not a dip within an uptrend).

Analysis as of 2026-11-13· more than 2 trading days ago

Company overview

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases. Its lead product, vonoprazan, is a potassium-competitive acid blocker in Phase III trials for GERD and H. pylori infection. The company holds commercial rights in the U.S., Europe, and Canada.

Fundamental

fair
Fundamental3
Mixed fundamentals

Phathom shows mixed fundamentals with improving revenue and profitability, but faces high leverage and single-product risk.

Mixed fundamentals with a strong operating inflection: TTM revenue ~$239.7M (roughly +110% y/y) at ~83% gross margin, a first operating-profitable quarter excluding stock-based compensation in Q2 2026, operating cash flow near breakeven (-$1.9M), $182.5M cash, covenant compliance and no going-concern doubt - set against ~$560M of debt-like obligations at ~10% cost, negative book equity (-$344.3M), continued dilution, a trimmed FY2026 revenue guide ($310-325M), and negative DCF outputs (model breakdown). A credible turnaround carrying elevated balance-sheet and single-product risk - mixed/uncertain, watchlist material.

Sentiment

fair
Sentiment3
Indeterminate sentiment

Sentiment is weak with limited media coverage and retail interest, and a recent guidance cut impacting perception.

The window's dominant fresh driver is a material, announced product catalyst - the registrational Phase 3 pHalcon-NERD-302 start for VOQUEZNA in non-erosive GERD (2026-09-29, not yet priced) - set against a thin, mildly negative tape and a guidance-cut narrative still digesting; the sentiment delta is indeterminate (both windows returned only 2 scored items, below the 3-item sample threshold, at -0.15 each). Red-Flag Screen: no severe or moderate flags fired (law-firm solicitations remain low-confidence overhang only) - no cap applied.

Technical

fair
Technical3
Bounce attempt

Short-term momentum is improving, but the stock remains in a broader downtrend, lacking a clear entry point.

Mixed read: the intermediate/long-term frames are still bearish — price 6.06 sits essentially at its SMA20 (6.0645) and below EMA21 6.12, SMA50 6.97 and SMA200 10.03, with SMA50 < SMA200 and MACD line still negative (-0.35). But the short-term tape is repairing: MACD crossed above its signal (-0.45) with an expanding positive histogram (+0.10), RSI14 recovered from 28.8 (Nov 5) to 46.6, ADX14 has faded from 23.5 to 18.6, and price holds above EMA9 5.88, WMA9 5.80, WMA21 5.87, DEMA14 5.68, TEMA14 5.83 and daily VWAP 6.00 on a rising sequence of session lows (5.04 -> 5.15 -> 5.40 -> 5.78). That is a bounce attempt inside a downtrend rather than a confirmed uptrend, hence a 3. It is not tradable: the buy-stop breakout above the settled 6.38 swing high (trigger 6.39, structure stop 5.29) yields R/R 0.96, below the 1.0 floor, and the only limit alternative (pullback toward the 5.85-6.00 shelf) is a countertrend bid — price below SMA50 with MACD < 0, and below a declining SMA200 with SMA50 < SMA200 and no momentum reclaim — which the trend-alignment gate prohibits.

You’re looking at 2026-11-13 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.